Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated radiotherapy plus irinotecan liposome and retlirafusp alfa in advanced refractory solid tumors
ChiCTR2600132110Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome and retlirafusp alfa in Nonhematologic neoplasms, sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Objective response rate of target lesions. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
irinotecan liposomeretlirafusp alfa
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2600132110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132110.